mibefradil


Also found in: Wikipedia.

mibefradil

A calcium-channel blocker that vasodilates without reflex tachycardia, which was used to manage hypertension or chronic stable angina. It was pulled from the market due to its inhibition of the liver metabolism of certain drugs (e.g., antihistamines) and statins, and increased mortality in patients with congestive heart failure.

mibefradil

Posicor® Cardiology A CCB that vasodilates without reflex tachycardia, used to manage HTN and angina pectoris; it was pulled from the market as it inhibits liver metabolism of certain drugs–eg, antihistamine, Histamal, and statin cholesterol-lowering agents. See Calcium channel blocker.
References in periodicals archive ?
Drug Profiles mentioned in this report are afatinib dimaleate, alisertib, AXL-1717, bevacizumab, CC-122, CDX-1401, Dendritic Cell Therapy for Gliomas, Dendritic Cell Therapy for Oncology, DNX-2401, ETS-2101, galunisertib, mibefradil dihydrochloride, nilotinib, palbociclib, panobinostat, pelareorep, plerixafor, Stem Cell Therapy for Glioma, temsirolimus and vocimagene amiretrorepvec + flucytosine ER.
ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.
lacidipine, lercanidipine, manidipine, mibefradil nicardipine,
Sildenafilin klirensini uzatan ilaglar Amiodarone Cerivasatin Atorvastatin Disopyramide Digitoxin Simvastatin Losartan Quinidine Felodidine Verapamil Lovastatin Mibefradil Diltiazem Isradipine Nifedipine
Their study found that mibefradil had the same effect as the dihydropyridines in lowering blood pressure, yet with lower fluid filtration, suggesting that mibefradil is not as harmful to vascular permeability in hypertensive rats as dihydropyridines.
The Prescription Drug User Fee Act and FDAMA provisions have had positive effects on accelerated development and expanded access, but several drugs were withdrawn from the market after the new laws (eg, mibefradil, dexfenfluramine, terfenadine, bromfenac, and troglitazone) and debate ensued.
Mibefradil (Posicor), a potent inhibitor of CYP3A4, was withdrawn from the market after numerous reports of serious drug-drug interactions.
Made from the drug mibefradil, the hexagonal tablets belong to a relatively new class of drug called calcium channel blockers.
The 30-patient dose escalation trial evaluated the detailed pharmacokinetics of mibefradil administered four times a day and confirmed its safe dose levels for use in a Phase 1b trial.
Concomitant therapy with the tetralol-class calcium channel blocker mibefradil (see PRECAUTIONS, Drug Interactions).
The Phase 1b trial is a dose escalation trial of Interlaced Therapy[TM] -- using Tau's first product candidate mibefradil sequentially administered with a cytotoxic drug -- in patients with recurrent high-grade glioma.
Tau Therapeutics is repositioning former hypertension drug, mibefradil dihydrochloride, in its Interlaced Therapy[TM] method to treat solid tumor cancers.